连续血糖监测对青少年和年轻成人1型糖尿病血糖控制的影响:一项随机临床试验
该随机临床试验纳入153例14-24岁、筛查HbA1c为7.5%-10.9%的1型糖尿病青少年和年轻成人,比较连续血糖监测(CGM)与常规血糖仪监测(BGM)对26周血糖控制的影响。结果显示CGM组HbA1c从基线8.9%降至26周8.5%,BGM组维持8.9%,组间校正差异为-0.37%(95%CI,-0.66%至-0.08%;结论认为CGM相比标准血糖监测在26周内带来小幅但统计学显著的血糖控制改善。
要点
- CGM组26周HbA1c较BGM组校正后降低0.37%(95%CI -0.66%至-0.08%)。
- CGM组68%的参与者在第6个月每周至少使用CGM 5天。
- 需进一步研究以理解该HbA1c改善的临床重要性。
核心结论
- 在1型糖尿病青少年和年轻成人中,CGM相比标准血糖监测在26周内带来小幅但统计学显著的血糖控制改善。
- 需要进一步研究以理解该发现的临床重要性。
研究设计与样本
- 随机临床试验,2018年1月至2019年5月在美国14家内分泌科实践点开展。
- 纳入153例14-24岁、筛查HbA1c为7.5%-10.9%的1型糖尿病患者。
- 按1:1随机分为CGM组(n=74)和常规血糖仪监测BGM组(n=79)。
- 主要结局为基线至26周HbA1c变化,另设20项次要结局并校正多重比较。
主要发现
- 153例参与者平均(SD)年龄17(3)岁,76例(50%)为女性,平均(SD)糖尿病病程9(5)年,142例(93%)完成研究。
- 20项预设次要结局中,7项二分类HbA1c结局有3项、9项CGM指标有8项、4项患者报告结局有1项差异有统计学意义。
- CGM组68%的参与者在第6个月每周至少使用CGM 5天。
- 最常见不良事件包括严重低血糖(CGM组3例、BGM组2例)、高血糖/酮症(CGM组1例、BGM组4例)和糖尿病酮症酸中毒(CGM组3例、BGM组1例)。
临床怎么用
- 对于1型糖尿病青少年和年轻成人,可考虑使用CGM以小幅改善HbA1c。
- 临床决策时应结合患者具体情况,并认识到该血糖改善幅度的临床重要性尚待明确。
局限性
- 原文未明确报告局限性,需进一步研究以理解HbA1c改善的临床重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes across the lifespan. Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents and young adults has not been demonstrated. OBJECTIVE: To determine the effect of CGM on glycemic control in adolescents and young adults with type 1 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted between January 2018 and May 2019 at 14 endocrinology practices in the US including 153 individuals aged 14 to 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%. INTERVENTIONS: Participants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood glucose meter for glucose monitoring (blood glucose monitoring [BGM] group; n = 79). MAIN OUTCOMES AND MEASURES: The primary outcome was change in HbA1c from baseline to 26 weeks. There were 20 secondary outcomes, including additional HbA1c outcomes, CGM glucose metrics, and patient-reported outcomes with adjustment for multiple comparisons to control for the false discovery rate. RESULTS: Among the 153 participants (mean [SD] age, 17 [3] years; 76 [50%] were female; mean [SD] diabetes duration, 9 [5] years), 142 (93%) completed the study. In the CGM group, 68% of participants used CGM at least 5 days per week in month 6. Mean HbA1c was 8.9% at baseline and 8.5% at 26 weeks in the CGM group and 8.9% at both baseline and 26 weeks in the BGM group (adjusted between-group difference, -0.37% [95% CI, -0.66% to -0.08%]; P = .01). Of 20 prespecified secondary outcomes, there were statistically significant differences in 3 of 7 binary HbA1c outcomes, 8 of 9 CGM metrics, and 1 of 4 patient-reported outcomes. The most commonly reported adverse events in the CGM and BGM groups were severe hypoglycemia (3 participants with an event in the CGM group and 2 in the BGM group), hyperglycemia/ketosis (1 participant with an event in CGM group and 4 in the BGM group), and diabetic ketoacidosis (3 participants with an event in the CGM group and 1 in the BGM group). CONCLUSIONS AND RELEVANCE: Among adolescents and young adults with type 1 diabetes, continuous glucose monitoring compared with standard blood glucose monitoring resulted in a small but statistically significant improvement in glycemic control over 26 weeks. Further research is needed to understand the clinical importance of the findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03263494.
引用
- Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32543683. doi:10.1001/jama.2020.6940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。